Protocol Ledger

NCT06797297 · Phase II · ACTIVE NOT RECRUITING

A Study to Evaluate the Efficacy and Safety of IBI363 Monotherapy Compared to Pembrolizumab in Patients With Unresectable Locally Advanced or Metastatic Mucosal or Acral Melanoma Who Had Not Previously Received Systemic

Interventional Phase II clinical trial protocol NCT06797297 sponsored by Innovent Biologics (Suzhou) Co in Oncology and Hematology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2025-02-24 Enrollment: 203 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT06797297
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)203 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT06797297
Protocol FieldVerified Registry Value
NCT IdentifierNCT06797297
Consolidated Lead SponsorInnovent Biologics (Suzhou) Co
Therapeutic Condition CohortOncology and Hematology
Clinical Trial PhasePhase II
Overall Recruitment StatusACTIVE NOT RECRUITING
Registered Enrollment203 participants (ACTUAL)
Registered Start Date2025-02-24
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Search related sites and sponsors in the Interactive Directory, explore Oncology and Hematology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI